Shereen Ezzat

Prof. Dr. Shereen Ezzat

Medicine & Oncology, University of Toronto; Head, Endocrine Oncology Site Group, University Health Network; Toronto General Hospital, Endocrine Oncology, Canada

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2007 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
SLSiobhan Loeper
Siobhan Loeper
SEShereen Ezzat
Shereen Ezzat

1 November 1998 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
SSSonia L. Sugg
Sonia L. Sugg
SEShereen Ezzat
Shereen Ezzat
IRIrving B. Rosen
Irving B. Rosen
JFJeremy L. Freeman
Jeremy L. Freeman
Sylvia L. AsaSylvia L. Asa
Sylvia L. Asa
Rearrangements involving the RET protooncogene have been implicated in the development of papillary thyroid carcinoma (PC). Transgenic mice, expressing thyroid-targeted RET/PTC-1, develop PC; but the clinical significance of this oncogene remains uncertain. We examined the expression of RET/PTC-1, -2, and -3 in human thyroid microcarcinomas and clinically evident PC to determine its role in early stage vs. developed PC and to examine the diversity of RET/PTC in multifocal disease. RNA was extracted from paraffin-embedded microcarcinomas and clinically evident PCs; the results obtained from paraffin-embedded tissue were confirmed on RNA from corresponding snap-frozen tissue of clinically evident PCs. RT and PCR was performed using primers for RET/PTC-1, -2, and -3; PGK-1 (the housekeeping gene) analysis was used to ensure integrity of the RNA and efficiency of the RT reaction. PCR products were resolved by gel electrophoresis, and Southern hybridization was performed with RET/PTC-1, -2, and -3 probes. A polyclonal antibody to the carboxyterminus of RET was used for immunohistochemistry on paraffin sections. Thirty-nine occult papillary thyroid microcarcinomas from 21 patients were analyzed. Of the 30 tumors (77%) positive for RET/PTC rearrangements, 12 were positive for RET/PTC-1, 3 for RET/PTC-2, 6 for RET/PTC-3, and 9 for multiple RET/PTC oncogenes. In clinically evident tumors, 47% had RET/PTC rearrangements. Immunohistochemistry demonstrated close correlation with RT-PCR-derived findings. RET/PTC expression is highly prevalent in microcarcinoma and occurs more frequently than in clinically evident PC (P < 0.005). Multifocal disease, identified in 17 of the 21 patients, exhibited identical RET/PTC rearrangements within multiple tumors in only 2 patients; the other 15 patients had diverse rearrangements in individual tumors. Our results indicate that RET/PTC oncogene rearrangements may play a role in early-stage papillary thyroid carcinogenesis, but they seem to be less important in determining progression to clinically-evident disease. In multifocal disease, the diversity of RET/PTC profiles, in the majority of cases, suggests that individual tumors arise independently in a background of genetic or environmental susceptibility.

1 June 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
SSSimron Singh
Simron Singh
Sylvia L. AsaSylvia L. Asa
Sylvia L. Asa
CDChris Dey
Chris Dey
HKHagen Kennecke
Hagen Kennecke
DLDavid Laidley
David Laidley
DRDaniel Rayson
Daniel Rayson

31 January 2019 in Endocrine Pathology
Verified
Journal Article
Closed access
PDF file
OAOmalkhaire M. Alshaikh
Omalkhaire M. Alshaikh
Sylvia L. AsaSylvia L. Asa
Sylvia L. Asa
OMOzgur Mete
Ozgur Mete
SEShereen Ezzat
Shereen Ezzat

20 July 2011 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
SCSonia Cheng
Sonia Cheng
LGLudovica Grasso
Ludovica Grasso
JMJose A. Martinez‐Orozco
Jose A. Martinez‐Orozco
RARany Al‐Agha
Rany Al‐Agha
RPRosario Pivonello
Rosario Pivonello
SEShereen Ezzat
Shereen Ezzat

8 December 2011 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
TTToru Tateno
Toru Tateno
Sylvia L. AsaSylvia L. Asa
Sylvia L. Asa
LZLei Zheng
Lei Zheng
TMThomas Mayr
Thomas Mayr
AUAxel Ullrich
Axel Ullrich
SEShereen Ezzat
Shereen Ezzat
Pituitary tumors are common intracranial neoplasms, yet few germline abnormalities have been implicated in their pathogenesis. Here we show that a single nucleotide germline polymorphism (SNP) substituting an arginine (R) for glycine (G) in the FGFR4 transmembrane domain can alter pituitary cell growth and hormone production. Compared with FGFR4-G388 mammosomatotroph cells that support prolactin (PRL) production, FGFR4-R388 cells express predominantly growth hormone (GH). Growth promoting effects of FGFR4-R388 as evidenced by enhanced colony formation was ascribed to Src activation and mitochondrial serine phosphorylation of STAT3 (pS-STAT3). In contrast, diminished pY-STAT3 mediated by FGFR4-R388 relieved GH inhibition leading to hormone excess. Using a knock-in mouse model, we demonstrate the ability of FGFR4-R385 to promote GH pituitary tumorigenesis. In patients with acromegaly, pituitary tumor size correlated with hormone excess in the presence of the FGFR4-R388 but not the FGFR4-G388 allele. Our findings establish a new role for the FGFR4-G388R polymorphism in pituitary oncogenesis, providing a rationale for targeting Src and STAT3 in the personalized treatment of associated disorders. Several human cancers have been associated with increased growth hormone levels. Here we show that a frequent single nucleotide polymorphism (SNP) associated with increased cancer risk and progression also deregulates pituitary function. Through recruitment of a distinct STAT3 signaling cascade, this polymorphic receptor variant drives pituitary growth hormone cell survival and hormonal output. These findings provide an example of a potentially common genetic program shared between cancer and a hormone that promotes its progression.